Notoginsenoside Ft1
Catalog No: CFN90859
Notoginsenoside Ft1 is a novel stimulator of angiogenesis, it stimulates angiogenesis via HIF-1α-mediated VEGF expression, with PI3K/AKT and Raf/MEK/ERK signaling cascades concurrently participating in the process; it has the potential therapeutic effect on human neuroblastoma, it can arrest the proliferation and elicited the apoptosis of SH-SY5Y cells possibly via p38 MAPK and ERK1/2 pathways.Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Notoginsenoside Ft1 also provides a great potential application of it in clinics for patients with diabetic foot ulcers, it may accelerate diabetic wound healing by orchestrating multiple processes, including promoting fibroblast proliferation, enhancing angiogenesis, and attenuating inflammatory response.
Lysicamine
Catalog No: CFN93254
Lysicamine shows significant antioxidant capacity in the ORAC(FL) assay and it is active against S. epidermidis and C. dubliniensis, with MIC values in the range 12.5-100 microg mL(-1). Lysicamine has antimicrobial and anti-inflammation activity, the minimum inhibitory concentrations of the pour component (Streptococcus mutans, Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Candida albicans.) is less than 5mg/ml for all four microorganisms and the minimum concentration with anti-inflammation is 0.2mg/ml for both IL-8 and IL-6. Lysicamine has antileishmanial activity. It can significantly inhibit the proliferation of melanoma cells, it has antioxidative activity and chemopreventive activity in skin melanoma cells.
